Werewolf Therapeutics, Inc. — Director's Dealing 2021

Apr 29, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-04-29

Reporting Person: Lubman Ellen (Chief Business Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.56	2030-08-02	Common Stock (145531)		Direct
Stock Option (right to buy)	$4.77	2030-12-07	Common Stock (118781)		Direct

Footnotes

F1: The option was granted on August 3, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through August 3, 2024.

F2: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.